Markets:

Overview

News

Currencies

International

Treasuries

Viatris Inc. - Common Stock (NQ:VTRS)

17.32 -0.27 (-1.53%)

Streaming Delayed Price Updated: 11:30 AM EDT, Jul 22, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Viatris Inc. - Common Stock

< Previous 1 2

...

8 9 10 11 12 13 14 15 16

...

22 23 Next >

The Terrible Ten ↗

February 23, 2024

Most of the aforementioned group of quotable experts expect some mean reversion for the top stocks in the S&P 500 and counsel avoiding market cap weighting in favor of equal weighting.

Via Talk Markets

Topics Stocks

The Terrible Ten ↗

February 12, 2024

Many strategists recommend equal weighting over cap-weighting, claiming that over time, equal weighting always outperforms.

Via Talk Markets

(VTRS) - Analyzing Viatris's Short Interest ↗

January 23, 2024

Via Benzinga

These 9 Stocks Are Running To Start 2024 ↗

January 14, 2024

The S&P 500 is up just 0.2% in 2024. These stocks are off to a strong start.

Via Investor's Business Daily

Topics Stocks

Regeneron Pharma's Pipeline Makes This Analyst Turn Bullish ↗

January 12, 2024

Regeneron Pharmaceuticals Inc (NASDAQ: REGN) won a lawsuit last month against Viatris Inc (NASDAQ: VTRS)

Via Benzinga

Topics Lawsuit

Recap: Viatris Q3 Earnings ↗

November 07, 2023

Via Benzinga

2 Top Value Stocks to Buy in October ↗

October 08, 2023

These two blue chip stocks offer top-notch yields, attractive valuations, and solid long-term prospects.

Via The Motley Fool

Beat Inflation With These 3 High-Yielding Dividend Stocks In Health Care Sector From Wall Street's Most Accurate Analysts ↗

January 12, 2024

During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high...

Via Benzinga

Topics Economy

Are defensive sectors ready to outshine growth in 2024?

January 06, 2024

Is 2024 the year defensive stocks rotate into leadership? As the year gets underway, defensives such as healthcare, energy, utilities and consumer staples lead.

Via MarketBeat

Why Is Lung Disease Focused Theravance Biopharma Stock Trading Lower Today? ↗

January 05, 2024

Theravance Biopharma Inc (NASDAQ: TBPH) announced results from the Phase 4 PIFR-2 study of Yupelri (revefenacin) inhalation solution, the only once-daily, nebulized long-acting muscarinic antagonist...

Via Benzinga

Tech Sell-Off Triggers Market Reset: Value Stocks Reach 7-Month High Versus Growth ↗

January 03, 2024

U.S. stock market suffered worst start in two decades, tech sell-off led to cautious investor shift to value stocks, notably IUSV & IUSG ETFs + top gainers MRNA, VTRS, TNL, LVS & VAC.

Via Benzinga

Topics ETFs

VIATRIS ALERT: Bragar Eagel & Squire, P.C. is Investigating Viatris Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

January 01, 2024

From Bragar Eagel & Squire

Via GlobeNewswire

Regeneron Celebrates Legal Win: Court Upholds Eylea Medication Patent ↗

December 28, 2023

Wednesday, a court ruling that found Viatris Inc's (NASDAQ:

Via Benzinga

3 Minutes To Boost Your Earnings: 3 Stocks With Over 3% Dividend Yields In Health Care Sector From Wall Street's Most Accurate Analysts ↗

December 27, 2023

Via Benzinga

A Look Into Healthcare Sector Value Stocks ↗

December 25, 2023

Via Benzinga

These 3 Dividend Stocks Are Undervalued Using This Key Valuation Metric ↗

November 30, 2023

Book value is a valuable metric for discovering undervalued stocks. These 3 dividend payers are trading below book value.

Via Talk Markets

Buy Alert: Analysts Say These 3 Growth Stocks Could Double in 2024 ↗

November 30, 2023

Often the best investments are out-of-favor and trade at silly cheap valuations. Check out three such growth stocks with huge upside.

Via InvestorPlace

7 Low P/E Stocks Poised to Rebound ↗

November 20, 2023

Each of these seven low P/E value stocks trades for under 10 times earnings, but could rise to a much higher valuation as sentiment improves.

Via InvestorPlace

Week In Review: Legend Partners DLL3 CAR-T Candidate With Novartis In $1.2 Billion Deal ↗

November 18, 2023

Legend Biotech partnered its DLL3 CAR-T candidates to Novartis in a $1.2 billion agreement, with $100 million offered upfront. Novartis will own worldwide rights to develop, manufacture, and...

Via Talk Markets

5 Value Stocks To Watch In The Healthcare Sector ↗

November 13, 2023

Via Benzinga

3 Large-Cap Stocks to Buy Trading Below Book Value ↗

November 07, 2023

There aren’t too many large-cap stocks in the S&P 500 trading below book value. But here are three possibilities.

Via InvestorPlace

Topics Stocks

Ozempic Just Shrugged Off a Challenge From Viatris. What Does This Mean for Investors? ↗

October 31, 2023

Viatris now faces a narrower path to commercializing a generic copy of Ozempic.

Via The Motley Fool

Viatris Just Sold Off 3 Key Segments. Is It Still a Buy? ↗

October 13, 2023

There's a chance shareholders won't notice any difference.

Via The Motley Fool

2 Healthcare Dividend Stocks You'd Regret Not Buying on the Dip ↗

October 08, 2023

These stocks may not be for everyone, but income-seekers might find what they're looking for in them.

Via The Motley Fool

Obesity Drug Wegovy's Triumph to Catapult Novo Holdings In Golden Era Of Wealth Boost ↗

October 03, 2023

Novo Holdings, the controlling shareholder of Novo Nordisk A/S (NYSE: NVO), is bracing for a significant influx of capital stemming from the thriving success of the weight-loss drug Wegovy.

Via Benzinga

Earnings Scheduled For November 7, 2023 ↗

November 07, 2023

Companies Reporting Before The Bell • CorEnergy Infr Tr (NYSE:CORR) is estimated to report earnings for its third quarter.

Via Benzinga

'Airbnb Has Foundational Cracks', Disney+ Follows Netflix On Subscription Sharing Crackdown, Microsoft's Nadella Criticizes Google's Exclusive Content Deals: Today's Top Stories ↗

October 03, 2023

Benzinga

Via Benzinga

Novo Nordisk Weight Loss Drug Patent Battle Against Viatris - Emerges As Winner ↗

October 03, 2023

Novo Nordisk A/S (NYSE: NVO) successfully defended two pivotal patent claims linked to the main ingredient in its popular weight-loss and diabetes drugs,

Via Benzinga

Topics Intellectual Property

Viatris Stock Bounds Higher As Divestitures Reach Nearly $7 Billion ↗

October 02, 2023

The company is retaining the rights to specific over-the-counter drugs in some markets.

Via Investor's Business Daily

Viatris Phase 1 Asset Divestiture Story: Plans To Sell Certain OTC Products, Women's Healthcare Business & More ↗

October 02, 2023

Viatris Inc (NASDAQ: VTRS) disclosed multiple deals to sell remaining assets to conclude Phase 1 of planned asset disposition by

Via Benzinga

< Previous 1 2

...

8 9 10 11 12 13 14 15 16

...

22 23 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Viatris Inc. - Common Stock (NQ:VTRS)

All News about Viatris Inc. - Common Stock

Starting at /week.